Pharmacological developments in male contraception

Bibliography

• BENNETT JP: Chemical contraception. Macmillan Press, New York (1974).
   Google Scholar
• MATLIN SA: Prospects for pharmacological male contra-ception. Drugs (1994) 48:851–863.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JE: Male reproductive function. In: Textbook of Endocrine Physiology. Griffin JE, Ojeda SR (Eds.), Oxford University Press, New York (1996):201–222.
   Google Scholar
• COSENTINO MJ, COCKETT ATK: Review article: structure and function of the epididymis. Urol. Res. (1986) 14:229–240.
   PubMed Web of Science ®Google Scholar
• KALRA SP, KALRA PS: Do testosterone and estradio1-1713enforce inhibition or stimulation of luteinizing hor-mone-releasing hormone secretion? Biol. Reprod. (1989) 41:559–570.
   Web of Science ®Google Scholar
• DEKRETSER DM, RISBRIDGER GP, KERR JB: Basic endocri-nology of the testis. In: Endocrinology. DeGroot LJ, Besser M, Burger HG, Jameson JL, Loriaux DL, Marshall JC, Odel WD, Potts JT, Jr., Rubenstein AH (Eds.), Saunders, Philadel-phia (1995):2307–2335.
   Google Scholar
• SCHALLY AV, KASTIN AJ, ARIMURA A: FSH -releasinghor-mone and LH-releasing hormone. Vitamins Hormones (1972) 30:83–164.
   PubMedGoogle Scholar
• FILICORI M, FLAMIGNI C: Treatment with GnRH analogs: controversies and perspetives. Parthenon Publishing Group, New York (1996).
   Google Scholar
• RIVIER JE, PORTER J, RIVIER CL et al: New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J. Med. Chem. (1986) 29:1846–1851.
   PubMed Web of Science ®Google Scholar
• PLO SKER GL, BROGDEN RN: Leuprore lin - a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disor-ders. Drugs (1994) 48:930–967.
   PubMed Web of Science ®Google Scholar
• LINDE R, DOELLE GC, ALEXANDER N et al.: Reversibleinhibition of testicular steroidogenesis and spermato-genesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the devel-opment of a male contraceptive. NewEngl. J. Med. (1981) 305:663–667.
   PubMed Web of Science ®Google Scholar
• KARTEN MJ, RIVIER JE: Gonadotropin-releasing hor-mone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr. Rev. (1986) 7:44–66.
   Google Scholar
• SANTEN RJ, BOURGUIGNON JP: Gonadotropin-releasing hormone: physiological and therapeutic aspects, agonists and antagonists. Hormone Res (1987) 28:88–103.
   PubMed Web of Science ®Google Scholar
• PAVLOU SN, WAKEFIELD, ISLAND DP eta].: Suppression of pituitary-gonadal function by a potent new luteiniz-ing hormone-releasing hormone antagonist in normal men. J. Clin. Endocrinol. Metab. (1987) 64:931–936.
   Google Scholar
• PAVLOU SN, BREWER K, FARLEY MG et al.: Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin. Endocrinol. Metab. (1991) 73:1360–1369.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, MATSUMOTO AM, CHRISTENSEN RB, RIVIER JE, BREMNER WJ: Comparison of a gonadotropin releas-ing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. (1993) 77:427–432.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, RIVIER JE, BREMNER WJ: Dose effects of thegonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadot-ropin levels in normal men. Fertil Steril. (1995) 64:139–145.
   PubMed Web of Science ®Google Scholar
• TOM L, BHASIN S, SALAMEH W et al: Induction ofazoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and tes-tosterone enanthate. j Clin. Endocrinol. Metab. (1992) 75:476–483.
   PubMed Web of Science ®Google Scholar
• WEINBAUER GF, NIESCHLAG E: Comparison of the an-tigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrore lix) in a non-human primate model (Maraca fascicularis). Andrologia (1993) 25:141–147.
   PubMed Web of Science ®Google Scholar
• WEINBAUER GF, NIESCHLAG E: Gonadotropin-releasing hormone analogue-induced manipulation of testicular function in the monkey. Human Reprod. (1993) 8\(Suppl. 2)45–50.
   Google Scholar
• FRASER HM: LHRH analogues: manipulation of pituitary-ovarian function in macaques and potential clinical and contraceptive applications. In: Hormone Antagonists for Fertility Regulation. Puri CP, Van Look PFA (Eds.), Indian Society for the Study of Reproduction and Fertility, Bombay (1989) :35–61.
   Google Scholar
• BEHRE HM, NASHAN D, HUBERT W, NIESCHLAG E: Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J. Clin. Endocrinol Metab. (1993) 74:84–90.
   Web of Science ®Google Scholar
• CUMMINGS DE, BREMNER WJ: Prospects for new hormo-nal male contraceptives. Endocrinol Metab. Clin. North Am. (1994) 23:893–922.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, STEINER B, CALLEGARI C, BHASIN B: GnRH analogues and male contraception. In: Pharma-cology Biology and Clinical Applications of Androgens Bhasin S, Galbelnick HL, Speller JM, Swerdloff RS, Wang C, Kelly C (Eds.), Wiley-Liss, New York (1996):355–365.
   Google Scholar
• NIESCHLAG E, WEINBAUER GF, BEHRE HM: Male contra-ception based on testosterone in combination with other agents. In: Pharmacology Biology and Clinical Ap-plications ofAndrogens. Bhasin S, Galbelnick HL, Speiler JM, Swerdloff RS, Wang C, Kelly C (Eds.), Wiley-Liss, New York. (1996):409–422.
   Google Scholar
• BEHRE HM, KLIESCH S, PUHSE G, REISSMANN T, NIESCH-LAG E: High loading and low maintenance doses of a gonadotropin-releasing antagonist suppress serum lute inizing hormone, follicle-stimulating hormone, and testosterone effectively in normal men. J. Clin. Endocrinol. Metab. (1997) 82 (In Press).
   Google Scholar
• BEHRE HM, KLIESCH S, LEMCKE B, NIESCHLAG E: Sup-pression of spermatogenesis to azoospermia by com-bined treatment of GnRH antagonist and 19-nortestosterone cannot be maintained by 19-nortestosterone alone in normal men. Proceedings of the 77th Annual Meeting of the Endocrine Society(1995): 0R29–
   Google Scholar
• NIESCHLAG E, BEHRE HM: Hormonal male contracep-tion: suppression of spermatogenesis with GnRH an-tagonists and testosterone. In: Treatment with GnRH Analogs: Controversies and Perspectives. Filicori M, Flamigni C (Eds.), Parthenon Publishing Group, New York (1996): 243–248.
   Google Scholar
• WEINBAUER GF, NIESCHLAG E: Reversibility of GnRHagonist-induced inhibition of testicular function: com-parison between rat, monkey and man. In: HIRHAgonists in Oncology Hoffken K, Niederle N (Eds.), Springer-Verlag, Berlin (1988):91.
   Google Scholar
• WEINBAUER GF, LIMBERGER A, BEHRE HM, NIESCHLAGE: Can testosterone alone maintain the gonadotropin-releas ing hormone antagonist-induced suppression of spermatogenesis in the non-human primate?' Endocri-nol. (1994) 142:485–495.
   Google Scholar
• NEGRO-VILAR A, LUMPKIN MD: Inhibin: central andperipheral effects to regulate follicle-stimulating hor-mone secretion. In: Male Reproduction and Fertility Ne-gro-Vilar A (Ed.), Raven Press, New York (1983):159–169.
   Google Scholar
• ZANELLI JM, ROSE M, GAINES DAS RE: Standardisation of inhibins: the international standard for porcine in-hibin and the proposed standard for recombinant hu-man inhibin. j Endocrinol. (1991) 131. Abstract No. 29.
   Google Scholar
• NIESCHLAG E: Reasons for abandoning immunisation against FSH as an approach to male fertility regulation. In: Male Contraception: Advances and Future Prospects. Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ (Eds.), Harper and Row, Philadelphia (1980395–400.
   Google Scholar
• SCHEARER SB, ALVAREZ-SANCHEZ F, ANSELMO J et al.:Hormonal contraception for men. Int. J. Androl. (1978) 2:680–712.
   Google Scholar
• BEBB RA, ANAWALT BD, CHRISTENSEN RB et al.: Com-bined administration of levonorgestrel and testoster-one induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol. Metab. (1996) 81:757–762.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, HOVVE CJ et al: Estab-lishing the minimum effective dose and additive effects of depot pr oges tin in suppression of human spermato-genesis by a testosterone depot. J. Clin. Endocrinol Metab. (1996) 81:4113–4121.
   PubMed Web of Science ®Google Scholar
• GONCHAROV NP, KATZIA GV, BUTNEV VU et al.: A non-human primate study (baboon; Papio hamadryas) to determine if a long-acting progestogen, levonorgestrel butanoate, combined with a long-acting androgen, tes-tosterone buciclate, can suppress spermatogenesis: I. Dose-finding study. Int. j Androl (1995) 18:75–82.
   PubMed Web of Science ®Google Scholar
• MEYER WI WALKER PA, EMORY LA, SMITH ER: Physical, metabolic and hormonal effects on men of long-term therapy with depot me droxyprogesterone acetate. Fer-til. Stern: (1985) 43:102–109.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO AM: Hormonal male contraceptive devel-opment: combined administration of androgens and pr oges togens . In: Pharmacology, Biology and Clinical Ap-plications ofAndrogens. Bhasin S, Galbelnick HL, Speller JM, Swerdloff RS, Wang C, Kelly C (Eds.), Wiley-Liss, New York (1996):367–374.
   Google Scholar
• COERT A, GEELEN J, DE VISSER J, VAN DER VIES J: Thepharmacology and metabolism of testosterone unde-canoate, a new orally active androgen. Acta Endocrinol (1975) 79:789–800.
   PubMedGoogle Scholar
• HORST HJ, HOLTGE WJ, DENNIS M et al. Lymphatic absorption and metabolism of orally administered tes- tosterone undecanoate in man. Kiln. Wschr. (1976) 54:875–879.
   PubMedGoogle Scholar
• NIESCHLAG E, MAUSS J, COERT A, KICOVIC P: Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocri-nol. (1975) 79:366–375.
   PubMedGoogle Scholar
• FREY H, AAKVAARG A, SAANUM D, FALCH J: Bioavailabil-ity of oral testosterone in males. Eur. j Clin. Pharmacol. (1979) 16:345–349.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BEHRE HM: Pharmacology and clinical uses of testosterone. In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM (Eds.), Springer Verlag, Berlin (1990):92–114.
   Google Scholar
• BEHRE HM, OBERPENNING, F, NIESCHLAG E: Compara-tive pharmacokinetics of androgen preparations: appli-cation of computer analysis and simulation In: Testosterone: Action, Deficiency, Substitution. Nieschlag E, Behre HM (Eds.), Springer Verlag, Berlin (1990):115–135.
   Google Scholar
• DJERASSI C, MIRAMONTEZ L, ROSENKRANZ G et al.: Ster-oids LIV. Synthesis of 19-nor-17a-ethynyltestosterone and 19-nor-17a -methyltestosterone. J. Am. Chem. Soc. (1954) 76:4092–4094.
   Google Scholar
• MATLIN SA: The pill - 40 years on. Educ. Chem. (1994): 123–126.
   Google Scholar
• GUERIN JF, ROLLET J: Inhibition of spermatogenesis inmen using various combinations of oral progestogens and percutaneous or oral androgens. Int. J Androl. (1988) 11:187–199.
   PubMed Web of Science ®Google Scholar
• MAUSS J, BORSCH G, RICHTER E, BORMACHERKL: Inves-tigations on the use of testosterone oenanthate as a male contraceptive agent. Contraception (1974) 10:281–289.
   PubMed Web of Science ®Google Scholar
• PATANELLI DJ: Hormonal control of male fertility. US Department of Health, Education and Welfare, Washington DC (1978) Publication no. (NIH) 78–1097.
   Google Scholar
• PAULSEN CA, BRENNER WJ, LEONARD JM: Male contra-ception: clinical trials. In: Advances in Fertility Research. Mishell DR, Jr. (Ed.), Raven Press, New York. (1982):157–170.
   Google Scholar
• MATSUMOTO AM: Is high dosage testosterone an effec-tive male contraceptive agent? Fertil. SteriL (1988) 50:324–328.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO AM: Effects of chronic testosterone ad-ministration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent sup-pression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J. Clin. Endocrinol. Metab. (1990) 70:282–287.
   PubMed Web of Science ®Google Scholar
• WALLACE EM, GOW SM, WU FCW: Comparison between testosterone enanthate-induced azoospermia and oli-gozoospermia in a male contraceptive study. I Plasma luteinizing hormone, follicle-stimulating hormone, tes-tosterone, estradiol and inhibin concentrations. J. aim Endocrinol Metab. (1993) 77:290–293.
   Web of Science ®Google Scholar
• KNUTH UA, BEHRE H, BELKIEN L et al.: 19-Nortestosterone for male fertility regulation. In: Male Contraception, Advances and Future Prospects. Zatuchni GI, Goldsmith A, Speiler JM, Sciarra JJ (Eds.), Harper and Row, Philadelphia (1986):320–328.
   Google Scholar
• BRENNER PF, MISHELL DR, BERNSTEIN GS, ORTIZ AO:Study of medroxyprogesterone acetate and testoster- one enanthate as a male contraceptive. Contraception (1977) 15:679–691.
   PubMed Web of Science ®Google Scholar
• WU FCW: Male contraception: current status and future prospects. Clin. Endocrinol (1988) 29:443–465.
   PubMed Web of Science ®Google Scholar
• WU FCW, AITKEN RJ: Suppression of sperm function by depot-medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fenn: Sten]. (1989) 51:691–698.
   PubMed Web of Science ®Google Scholar
• KNUTH UA, YEUNG C-H, NIESCHLAG E: Combination of19-nortestosterone hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone acetate (Cli-novir) for male contraception. Fertil. Sten]. (1989) 51:1011–1018.
   PubMed Web of Science ®Google Scholar
• BARFIELD A, MELO J, COUTINHO E et al.: Pregnanciesassociated with sperm concentrations below 10 mil-lion/ml in clinical studies of a potential male contra-ceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception (1979) 20:121–127.
   PubMed Web of Science ®Google Scholar
• WALLACE EM, AITKEN RJ, WU FCW: Residual spermfunction in oligozoospermia induced by testosterone enanthate administered as a potential male contracep-tive. Int. J. Androl (1992) 15:241–246.
   Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METH-ODS FOR THE REGULATION OF MALE FERTILITY: Contra-ceptive efficacy of testosterone-induced azoospermia in normal men. Lancet (1990) 336:955–959.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METH-ODS FOR THE REGULATION OF MALE FERTILITY: Com-parison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil. Sten]. (1993) 601:1062–1068.
   Google Scholar
• PANGKAHILA W: Reversible azoospermia induced by anandrogen-progestogen combination regimen in Indo-nesian men. Int. J. Androl. (1991) 14:248–256.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON METH-ODS FOR THE REGULATION OF MALE FERTILITY: Contra-ceptive efficacy of testoster one-induced azoospermiain normal men. Fertil Sten]. (1996) 65:821–829.
   PubMedGoogle Scholar
• ANDERSON RA, WU FCW: Comparison between testos-terone enanthate-induced azoospermia and oligo-zoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. Clin. Endocrinol. Metab. (1996) 81:896–901.
   Google Scholar
• BAGATELL CJ, HEIMAN JR, MATSUMOTO AM et al.: Meta-bolic and behavioral effects of high-dose exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. (1994) 79:561–567.
   PubMed Web of Science ®Google Scholar
• BARDIN CW, SWERDLOFF RS, SANTEN RJ: Androgens: risks andbenefits. j Clin. Endocrinol Metab. (1991) 73:4–7.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION SPECIAL PROGRAMMEOF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Guidelines for the use of androgens in men. WHO, Geneva (1992).
   Google Scholar
• WU FCW, FARLEY TMM, PEREGOUDOV A, WAITES GMH:Effects of testosterone enanthate in normal men: expe-rience from a multicenter contraceptive efficacy study. Fertil. Stern'. (1996) 65:626–636.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLA MC, MARCOVINA S, PAULSEN CA, BREMNER WJ: Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Androl (1995) 18:237–242.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, WALLACE EM, WU FCW: Effect of testos-terone enanthate on serum lipoproteins in man. Con-traception (1995) 52:115–119.
   Google Scholar
• Testosterone: Action, Deficiency Substitution. Nieschlag E, Behre HM (Eds.), Springer Verlag, Berlin (1990).
   Google Scholar
• BHASIN S, SWERDLOFF RS, STEINER B et al: A biodegrad-able testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. (1992) 74:75–83.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN L: Suppression of human spermatogenesis by testosterone implants. J. Clin. Endocrinol Metab. (1992) 75:1326–1332.
   PubMed Web of Science ®Google Scholar
• CRABBE P, DICZFALUSY E, DJERASSI C: Injectable contra-ceptive synthesis: an example of international Cu-pertino. Science (1980) 209:992–994.
   PubMed Web of Science ®Google Scholar
• MATLIN SA, CHAN L, PRAZERES MA et al: Long-acting androgens: analytical and preparative HPLC of testos-terone esters. J. High Resolution Chromatogr. Chromatogr. Commun. (1987) 10:186–190.
   Google Scholar
• RAJALAKSHMI M, RAMAKRISHNAN PR, KAUR J etal: Evalu-ation of the ability of a new long-acting androgen ester to maintain accessory gland function in the castrated rhesus monkey. Contraception (1991) 43:83–90.
   PubMed Web of Science ®Google Scholar
• WEINBAUER GF, MARSHALL GR, NIESCHIAG E: New in-jectable testosterone ester maintains serum testoster-one of castrated monkeys in the normal range for four months. Acta Endocrinol (1986) 113:128–132.
   PubMedGoogle Scholar
• BEHRE M, NIESCHLAG E: Testosterone buciclate (20AeT-1) in hypogonadal men: pharmacokinetics and phar-macodynamics of the new long-acting androgen ester. Clin. Endocrinol. Metab. (1992) 75:1204–1210.
   Google Scholar
• SHARMA RK, DAS RP: Effect of STS-557 and 20 Aet-1 onsperm functions and levels of testosterone in bonnet monkey (Maraca radiata). Contraception (1992) 45:483–491.
   PubMed Web of Science ®Google Scholar
• KINGER S, PAL PC, RAJALAKSHMI M et al.: Effects oftestosterone buciclate on testicular and epididymal sperm functions in bonnet monkeys (Maraca radiata). Contraception (1995) 52:121–127.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, BAUS S, KLIESCH S et al: Potential of testos-terone buciclate for male contraception: endocrine differences between responders and nonres ponders . Clin. Endocrinol. Metab. (1995) 80:2394–2403.
   Google Scholar
• SUNDARAM K, KUMAR N, BARDIN CW: 7a-methyl-nortestosterone (MENT): the optimal aidrogen for male contraception. Ann. Med. (1993) 25:199–205.
   PubMed Web of Science ®Google Scholar
• LIAO S, LIANG T, CASTANEDA E, SHAO T-C: Steroidstructure and androgenic activity. J. Biol. Chem. (1973) 248:6154–6162.
   PubMed Web of Science ®Google Scholar
• KUMAR N, DIDOLKAR AK, MONDER C, BARDIN CW, SUNDARAM K: The biological activity of 7a-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology (1992) 130:3677–3683.
   PubMed Web of Science ®Google Scholar
• SUNDARAM K, KUMAR N, BARDIN CW: 7a-methyl-19-nortestosterone: an ideal androgen for replacement therapy. Recent Prog. Horm. Res. (1994) 49:373–376.
   PubMedGoogle Scholar
• OGAWA S, ROBBINS A, KUMAR N et al: Effects of testos-terone and 7a-methyl-19-nortestosterone (MENT) on sexual and aggressive behaviors in two inbred strains of male mice. Horm. Behav. (1996) 30:74–84.
   PubMed Web of Science ®Google Scholar
• MORALI G, LEMUS AE, MUNGUlA R et al.: Induction of male sexual behavior in the rat by 7a-methyl-19-nortestosterone, an androgen that does not undergo 5 alpha-reduction. Biol. Reprod. (1993) 49:577–581.
   PubMed Web of Science ®Google Scholar
• LAMORTE A, KUMAR N, BARDIN CW, SUNDARAM K: Aromatization of 7a-methyl-19-nortestosterone by hu-man placental microsomes in vitro. J. Steroid Biochem. Mol. Biol. (1994) 48:297–304.
   PubMed Web of Science ®Google Scholar
• SUNDARAM K, KUMAR N, MONDER C, BARDIN CW: Dif-ferent patterns of metabolism determine the relative anabolic activity of 19-norandrogens. J. Steroid Biochem. Mol. Biol. (1995) 53:253–257.
   PubMed Web of Science ®Google Scholar
• THAU R, ROBBINS A: New implant systems for men and women. In: Contraceptive Research and Development 1984 to 1994. Van Look PFA, Perez-Palacios G (Eds.), Oxford University Press, Oxford (1994):91–106.
   Google Scholar
• WANG C, SVVERDLOFF RS, WAITES GMH: Male contracep-tion: 1993 and beyond. In: Contraceptive Research and Development 1984 to 1994 Van Look PFA, Perez-Palacios G (Eds.), Oxford University Press, Oxford (1994):121–134.
   Google Scholar
• PURANDARE TV, KHOLKUTE SD, GURJAR A eta].: Semen analysis and hormonal levels in bonnet macques ad-ministered Embelia ribes berries, an indigenous plant having contraceptive activity. Ind. J. Exp. Biol. (1979) 17:935–936.
   Google Scholar
• CHAUHAN S, AGRAWAL S, MATHUR R, GUPTA RK: Phos-phatase activity in testis and prostate of rats tr eated with embelin and Vinca rosea extract. Experientia (1979) 35:1183–1185.
   PubMedGoogle Scholar
• DIXIT VP, BHARGAVA SK: Reversible contraception like activity of embelin in male dogs (Canis indicus Linn). Andrologia (1983) 15:486–494.
   PubMed Web of Science ®Google Scholar
• GITHUI EK, MAKAWITI DW, MIDIWO JO: Changes in the concentrations of testosterone, luteinising hormone and progesterone associated with administration of embelin. Contraception (1991) 44 (3):311–317.
   PubMed Web of Science ®Google Scholar
• NATIONAL COORDINATING GROUP ON MALE FERTILITY AGENTS: Gossypol, a new antifertility agent for males. Chinese Med. J. (1978) 4:417–428.
   PubMed Web of Science ®Google Scholar
• QIAN SZ, WANG ZG: Gossypol: a potential antifertility agent for males. Ann. Rev. Pharmacol. Toxicol. (1984) 24:329–360.
   PubMed Web of Science ®Google Scholar
• WANG C, YEUNG RTT: Gossypol and hypokalemia. Con-traception (1985) 32:237–252.
   Google Scholar
• MATLIN SA, ZHOU RH, BELENGUER A eta].: Large scale resolution of gossypol enantiomers for biological evaluation. Contraception (1988) 37:229–237
   Google Scholar
• MATLIN SA, ZHOU RH, BIALY G et al: (-)-Gossypol: an active male antifertility agent. Contraception (1985) 31:141–149
   PubMed Web of Science ®Google Scholar
• LINDBERG MC, NAQVI RH, MATLIN SA et al: Comparative antifertility effects of gossypol enantiomers in male hamsters. Int. j Androl. (1987) 10:619–23
   PubMed Web of Science ®Google Scholar
• HEYVVOOD R, LLOYD GK, MAJEED SK, GOPINATH C: The toxicity of gossypol to the male rat. Toxicology (1986) 40:279–284.
   PubMed Web of Science ®Google Scholar
• HEYWOOD R C: The toxicity of gossypol-acetic acid and (-)-gossypol. Contraception (1988) 37:185–190.
   PubMed Web of Science ®Google Scholar
• COYLE T, LEVANTE S, SHETLER M, WINFIELD J: In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J. Neuro-OncoL (1994) 19:25–35.
   PubMed Web of Science ®Google Scholar
• ORHAN G, EKMEKI A, MENEVSE S: The effect of the male contraceptive agent gossypol acetic acid on mouse bone marrow cells in viva micronuclei and mitotic index. Contraception (1993) 47:377–385.
   PubMed Web of Science ®Google Scholar
• JOSEPH AEA, MATLIN SA, KNOX P: Cytotoxicity of enan-tiomers of gossypol. Br. J. Cancer (1986) 54:511–513.
   PubMed Web of Science ®Google Scholar
• BAND V, HOFFER AP, BAND H et aL: Antiproliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. Gynecol Oncol. (1989) 32:273–277.
   PubMed Web of Science ®Google Scholar
• BENZ CC, KENIRY MA, FORD JM et al.: Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol. Pharmacol (1990) 37:840–847.
   PubMed Web of Science ®Google Scholar
• QIAN SZ: Tripterygium wilfordii: a Chinese herb effec-tive in male fertility regulation. Contraception (1987) 36:335–345
   PubMed Web of Science ®Google Scholar
• HOOK F: Male antifertility compounds from Triptery-gium wilfordii. Contraception (1993) 47:387–400
   PubMed Web of Science ®Google Scholar
• MATLIN SA, BELENGUER A, STACEY VE et aL: Triptery-giumwilfordii: structure, chemistry andactivity of male antifertility constituents. Reproduction Contraception (1994) 5:145–254.
   Google Scholar
• QIAN SZ, XU Y, ZHANG JW: Recent progress in research on Tripterygium: a male antifertility plant. Contracep-tion (1995) 51:121–129.
   PubMed Web of Science ®Google Scholar
• COSENTINO MJ, CHEY WY, TAKIHARA H eta].: The effects of sulfasalazine on human male fertility potential and seminal prostaglandins. J. Urology (1984) 132:682–686.
   Google Scholar
• COSENTINO MJ, PAKYZ RE, FRIED J: Pyrimethamine: an approach to the development of a male contraceptive. Proc. Natl. Acad. Sci USA (1990) 87:1431–1435.
   PubMed Web of Science ®Google Scholar
• MALIK NS, MATLIN SA, FRIED J, PAKYZ R, COSENTINO MJ: The contraceptive effects of etoprine on male mice and rats. J. Androl. (1995)16:169–174.
   PubMed Web of Science ®Google Scholar
• COOK CE, WANI MC, JUMP JM et al.: Structure-activity studies of 2,3,4,4a,5,9b-hexahydroindeno[1,2-c]pyri-dines as antispermatogenic agents for male contracep-tion. J. Med. Chem. (1995) 38:753–763.
   PubMed Web of Science ®Google Scholar
• EBENOTHER A, BASTIAN JM, GRADIENT F: 1,3,4,4a,5,9b-hexahydro-5-phenyl -21-1-indeno[1,2-c]pyridine. U53678057 (1972).
   Google Scholar
• KEDIA KR, PERSKY L: Effect of phenoxybenzamine (dibenzyline) on sexual function in man. Urology (1981) 18:620–622.
   PubMed Web of Science ®Google Scholar
• AMOBI NIB, SMITH ICH: Differential inhibition in the human vas deferens by phenoxybenzamine: a possible mechanism for its contraceptive action. J. Reprod. Fertil. (1995) 103:215–221.
   PubMedGoogle Scholar
• HOMONNAI ZT, SHILON M, PAZ GF:Phenoxybenzamine: an effective male contraceptive pill. Contraception (1984) 29:479–489.
   PubMed Web of Science ®Google Scholar
• WAITES GMH: Post-testicular antifertility methods. Se-rono Symp. Publ. Raven Press, New York (1987) 36:247–263.
   Google Scholar
• FORD WCL, WAITES GMH: Sperm maturation and the potential for contraceptive interference. In: Male Con-traception: Advances and Future Prospects. Zatuchni GI, Goldsmith A, Speller JM, Sciarra JJ (Eds.), Harper and Row, Philadelphia (1986):89–106.
   Google Scholar
• FROMTLING RA: Overview of medically important anti-fungal azole derivatives. Clin. Nlicrobiol. Rev. (1988) 1:187–217.
   PubMedGoogle Scholar
• NAGAI K, MIYAMORY I, IKEDA M eta].: Effect of ketocona-zole (an imidazole antimycotic agent) and other inhibi-tors of steroidogenesis on cytochrome P450-catalyzed reactions. J. Steroid Biochem. (1986) 24:321.
   Google Scholar
• TRACHTENBERG J, HALPERN N, PONT A: Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J. Urol. (1983) 130:152–153.
   PubMed Web of Science ®Google Scholar
• SONINO N: The endocrine effects of ketoccnazole. Endocrinol. Invest (1986) 9:341–347.
   PubMed Web of Science ®Google Scholar
• RAJFER J, SIKKA SC, RIVERA F, HANDELSMAN DJ: Mecha-nism of inhibition of human testicular steroidogenesis by oral ketoconazole. j Clin. Endocrinol. Metab. (1986) 63:1193–1198.
   PubMed Web of Science ®Google Scholar
• SANTEN RJ, VAN DEN BOSSCHE H, SYMOENS J et aL: Sites of action of low dose ketoconazole on androgen bio-synthesis in men. J. Clin. Endocrinol Metab. (1983) 57:732–736.
   PubMed Web of Science ®Google Scholar
• GOODPASTURE JC, HILLER MB, LEWIS B et al: Same day appearance of orally administered, spermicidal 1-sub-stituted imidazoles in dog ejaculates. J. Androl. (1987) 8:230–237.
   PubMed Web of Science ®Google Scholar
• VICKERY BH, BURNS J, ZANEVELD LJD, GOODPASTURE JC, BERGSTROM K: Orally administered ketoconazole rapidly appears in seminal plasma and suppresses sperm motility. Adv. Contraception (1985) 1:341–353.
   PubMedGoogle Scholar
• VICKERY BH, GOODPASTURE JC, BERGSTROM K et aL: Assessment of a new spermicidal agent against ejacu-lated dog and human spermatozoa in vitro Fertil Stern: (1983) 40:231–236.
   Google Scholar
• HECKMAN WR, KANE BR, PAKYZ RE, COSENTINO MJ: The effect of ketoconazole on endocrine and reproductive parameters in male mice and rats./ Androl. (1992) 13:191–198.
   PubMed Web of Science ®Google Scholar
• VICKERY BH, GRIGG MB, GOODPASTURE JC et al.: To-wards a same-day, orally administered male contracep-tive. In: Male contraception: Advances and Future Prospects. Zatuchni GI, Goldsmith A, Speller JM, Sciarra JJ (Eds.), Harper and Row, Philadelphia (1986):271–292.
   Google Scholar
• PATANELLI DJ: Suppression of fertility in the male. In: Handbook of Physiology, Section 7 Endocrinology, Volume 5 Male Reproductive System. Greep RO, Hamilton DW (Eds.), American Physiology Society, Washington, DC (1975):245–258.
   Google Scholar
• MCCLAIN RM, DOWNING JC: The effect of ornidazole on fertility and epididymal sperm function in rats. Toxicol Applied PharmacoL (1988) 92:488–496.
   PubMed Web of Science ®Google Scholar
• OBERLANDER G, YEUNG CH, COOPER TG: Induction of reversible infertility in male rats by oral ornidazole and its effects on sperm motility and epididymal secretions. Reprod. Fertil (1994) 100:551–559.
   PubMedGoogle Scholar
• OBERLANDER G, YEUNG CH, COOPER TG: Influence of oral administration of ornidazole on capacitation and the activity of some glycolytic enzymes of rat sperma-tozoa. J. Reprod. Fertil. (1996) 106:231–239.
   PubMedGoogle Scholar
• POTTS M: A male contraceptive pill [letter]. Nature Med. (1996) 2:722.
   Google Scholar
• GRIFFIN PD: A male contraceptive pill [letter]. Nature Med. (1996) 2:722.
   PubMedGoogle Scholar
• NIESCHLAG E, WAITES G: A male contraceptive pill [letter]. Nature Med. (1996) 2:722.
   PubMedGoogle Scholar